Eur Rev Med Pharmacol Sci 2020; 24 (12): 6786-6793

DOI: 10.26355/eurrev_202006_21667

Knockdown of FOXM1 suppresses cell growth and metastasis in human laryngeal cancer via the AKT signaling pathway

J. Yan, J. Hou, Y. Yan, X.-Y. Ren, H.-N. Luo, Z.-G. Wang, G.-X. Zheng

Department of Otolaryngology Head and Neck Surgery, Second Affiliated Hospital of Xi’an Jiaotong University, Xian, China. zhengguoxi@21cn.com


OBJECTIVE: This study aims to investigate the potential regulatory effect of forkhead box M1 (FOXM1) on laryngeal carcinoma (LC) and the underlying mechanisms.

PATIENTS AND METHODS: Tumor tissues were obtained from 80 patients diagnosed with LC in our hospital. Quantitative Real Time-Polymerase Chain Reaction (qRT-PCR) and Western blot analysis were used to detect the expression levels of FOXM1 in LC tissues and cell lines. Transfection of small interfering RNA (si-RNA) was conducted to knockdown the expression level of FOXM1. MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide) assay and cell colony assay were conducted to measure the changes in cell proliferation capacity influenced by FOXM1. Finally, invasion and migration ability was evaluated by the transwell assay.

RESULTS: FOXM1 was found upregulated in LC tissues and cells. Transfection of FOXM1 siRNA in LC cells successfully inhibited the expression of FOXM1. The knockdown of FOXM1 resulted in reduced proliferation, invasion, and migration of LC cells. Further studies indicated that the knockdown of FOXM1 suppressed the ratio of p-AKT/AKT. Besides, the impaired proliferation, invasion, and migration of LC cells induced by FOXM1 knockdown could be counteracted by application of the AKT activator Sc79.

CONCLUSIONS: The present work demonstrated that the knockdown of FOXM1 suppressed the proliferation, invasion, and migration of LC cells by the AKT signaling pathway.

Free PDF Download

To cite this article

J. Yan, J. Hou, Y. Yan, X.-Y. Ren, H.-N. Luo, Z.-G. Wang, G.-X. Zheng
Knockdown of FOXM1 suppresses cell growth and metastasis in human laryngeal cancer via the AKT signaling pathway

Eur Rev Med Pharmacol Sci
Year: 2020
Vol. 24 - N. 12
Pages: 6786-6793
DOI: 10.26355/eurrev_202006_21667